Literature DB >> 9389577

Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines.

H Burger1, K Nooter, A W Boersma, C J Kortland, G Stoter.   

Abstract

We investigated the role of p53 and of the Bcl-2 family proteins in the apoptotic response of a panel of testicular tumour cell lines (NT2, NCCIT, S2 and 2102 EP). The p53 gene status and the capacity of the p53 protein to transactivate the p21/WAF/CIP gene were determined, and we examined the correlation between p53 status and the susceptibility to cisplatin-induced apoptosis. In contrast to wild-type p53-containing NT2 and 2102 EP cells, NCCIT (mutant p53) and S2 (no p53 protein) cells were shown to be p53-transactivation defective. However, NCCIT and S2 cells with non-functional p53 were readily triggered into apoptosis by cisplatin, whereas p53-transactivation competent 2102 EP cells failed to undergo cisplatin-induced apoptosis. The defective apoptotic pathway in 2102 EP cells was reflected by a 4-fold decreased sensitivity to cisplatin in the MTT assay. We further demonstrated that the p53-independent differential cisplatin sensitivity among the testicular germ cell tumour (TGCT) cell lines was not due to differences in cellular cisplatin accumulation or DNA platination. The pattern of endogenous expression levels of Bax, Bcl-2, Bcl-x and Bak, which was not modulated by cisplatin treatment, demonstrated that these Bcl-2 family proteins are not involved in drug-induced apoptosis in the TGCT cell lines. Our results suggest a lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in our panel of TGCT cell lines. We conclude that the cisplatin-induced apoptotic pathway in TGCT cell lines might be p53-independent and is probably not associated with differences in the Bcl-2/Bax rheostat.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389577     DOI: 10.1002/(sici)1097-0215(19971114)73:4<592::aid-ijc22>3.0.co;2-a

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells.

Authors:  D B Zamble; T Jacks; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

2.  Personalised cancer care: promises and challenges of targeted therapy.

Authors:  Shi-Ming Tu; Mehmet A Bilen; Nizar M Tannir
Journal:  J R Soc Med       Date:  2016-03-01       Impact factor: 5.344

3.  Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Authors:  Mayur A Gadhikar; Maria Rita Sciuto; Marcus Vinicius Ortega Alves; Curtis R Pickering; Abdullah A Osman; David M Neskey; Mei Zhao; Alison L Fitzgerald; Jeffrey N Myers; Mitchell J Frederick
Journal:  Mol Cancer Ther       Date:  2013-07-09       Impact factor: 6.261

4.  Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.

Authors:  Frank Mayer; Sandra Mueller; Elke Malenke; M Kuczyk; Jörg T Hartmann; Carsten Bokemeyer
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

5.  Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent.

Authors:  Alessandra di Pietro; Roelof Koster; Wytske Boersma-van Eck; Wendy A Dam; Nanno H Mulder; Jourik A Gietema; Elisabeth G E de Vries; Steven de Jong
Journal:  Cell Cycle       Date:  2012-11-19       Impact factor: 4.534

6.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

7.  p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.

Authors:  Benjamin T Spike; Geoffrey M Wahl
Journal:  Genes Cancer       Date:  2011-04

8.  Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.

Authors:  Yingmei Liu; Xiaodan Lu; Sinh Nguyen; Jean L Olson; Heather K Webb; Deanna L Kroetz
Journal:  Mol Pharmacol       Date:  2013-10-03       Impact factor: 4.436

9.  Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).

Authors:  H Burger; A Zoumaro-Djayoon; A W M Boersma; J Helleman; E M J J Berns; R H J Mathijssen; W J Loos; E A C Wiemer
Journal:  Br J Pharmacol       Date:  2010-01-08       Impact factor: 8.739

10.  Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.

Authors:  Rathindra N Bose; Leila Maurmann; Robert J Mishur; Linda Yasui; Shefalika Gupta; W Scott Grayburn; Heike Hofstetter; Tara Salley; Tara Milton
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.